Patients with refractory metastatic colorectal cancer experience...
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy...
Neoadjuvant immunotherapy improves outlook in high-risk...
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous...
Dual-targeting CAR NK cells can prevent cell dysfunction...
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to engineering natural killer (NK)...
Dietary supplementation may improve antibiotic-induced GVHD...
Researchers at The University of Texas MD Anderson Cancer Center have identified a specific gut bacterium involved in the progression...
MD Anderson Research Highlights for September 28, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...
MD Anderson celebrates World Cancer Research Day
The University of Texas MD Anderson Cancer Center again supports World Cancer Research Day, Sept. 24, and its goals to highlight...
CPRIT awards $2.5 million to support MD Anderson cancer...
The University of Texas MD Anderson Cancer Center was awarded $2.5 million today from the Cancer Prevention and Research Institute of...
MD Anderson Research Highlights for September 14, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...
MD Anderson and Radiopharm Theranostics launch joint...
The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics today announced the launch of Radiopharm Ventures, LLC,...
Tumor-infiltrating B cells and plasma cells influence...
Through extensive single-cell analysis, researchers at The University of Texas MD Anderson Cancer Center have created a spatial map of...
RET inhibitor selpercatinib demonstrates durable responses...
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor...
Immunotherapy before surgery induces complete response in...
ABSTRACT 789O
In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center,...
HER2-low metastatic breast cancer patients report preserved...
ABSTRACT 2170O
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2...
MD Anderson Research Highlights: ESMO 2022 Special Edition
ABSTRACTS 735MO, 316O, 1MO, 1493MO, 457MO, 283MO, LBA68, 785O
The University of...
MD Anderson and Virogin Biotech announce strategic...
The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the...
Swathi Arur named Emerging Leader in Health and Medicine...
Swathi Arur, Ph.D., professor and deputy chair of Genetics at The University of Texas MD Anderson Cancer Center, has been selected as...